Biocon Biologics has made a significant move in the biopharmaceutical industry by acquiring the biosimilars business of Viatris for nearly $3 billion. This strategic acquisition positions Biocon to enhance its presence in key markets while expanding its product offerings.
Financial Breakdown of the Acquisition
The deal consists of an up-front payment of $2.3 billion, alongside Compulsorily Convertible Preference Shares valued at $1 billion. Overall, the transactions are valued at approximately $3.3 billion, a figure that has received approval from the boards of both Biocon Biologics and Viatris.
Strengthening Global Reach
Kiran Mazumdar-Shaw, the executive chairperson of Biocon Biologics, emphasized the importance of this acquisition for the company’s future. She stated that it would not only build a strong commercial engine in developed markets such as the United States and Europe but also fast-track Biocon’s goal of becoming a prominent global brand. This collaboration with Viatris reflects their mutual commitment to improving global health by making essential biosimilar drugs more accessible.
Biocon Biologics: A Profile
Biocon Biologics, based in Bengaluru, India, operates as a subsidiary of Biocon. The parent company has a rich history in the development of biologics. Viatris, on the other hand, was formed through the merger of Mylan and Pfizer’s Upjohn division, with its headquarters located in Canonsburg, Pennsylvania.
Unlocking Stakeholder Value
Arun Chandavarkar, managing director at Biocon Biologics, highlighted the anticipated benefits of merging Viatris’ biosimilars business. By integrating these assets, Biocon aims to unlock substantial value for its stakeholders. The acquisition grants Biocon complete ownership of Viatris’ biosimilars rights, allowing for a unified approach to revenue generation and profit realization. To facilitate a smooth transition, Viatris will provide commercial and other support services to Biocon Biologics for a period of two years.
Current Portfolio of Biocon Biologics
Biocon Biologics boasts eight approved biosimilars in various international markets. Notably, it markets Semglee, the first biosimilar of insulin glargine and the first interchangeable biosimilar approved by the FDA. Biocon shares commercialization rights for Semglee with Viatris, showcasing their collaborative efforts in the biosimilars space.
Viatris’ Contributions to the Biosimilar Market
Viatris also holds FDA approval for an adalimumab biosimilar known as Hulio, which is set to enter the market in 2023. Additionally, the company received approval for its etanercept biosimilar, Nepexto, by the European Medicines Agency in May 2020. These products reference established therapies like Humira and Enbrel, further demonstrating Viatris’ commitment to providing affordable treatment options.
Collaborative Products and Ongoing Research
In their joint efforts, Biocon Biologics and Viatris share commercialization rights for Abevmy, a biosimilar referencing Avastin. Recent phase 3 studies published in November 2021 indicated that Abevmy displayed comparable safety and efficacy to the reference product in patients with advanced lung cancer, emphasizing the potential of their combined offerings.
Strategic Implications for Viatris
Robert J. Coury, the executive chairman at Viatris, expressed confidence that this transaction would optimize Viatris’ involvement in the biosimilars sector, allowing the company to focus on its financial goals. This strategic shift is expected to lead to improved operational efficiency while continuing to engage in the global biosimilars market.
Looking Ahead
This acquisition marks a pivotal moment for both Biocon Biologics and Viatris. By merging their resources and expertise, they are well-positioned to enhance patient access to affordable biologics. The collaboration signals a significant step forward in the biosimilars landscape, promising to deliver innovative solutions for patients worldwide.
In conclusion, the acquisition of Viatris’ biosimilars business is a transformative event for Biocon Biologics. It not only strengthens their market position but also exemplifies a commitment to improving global health outcomes. As both companies leverage their combined capabilities, they are set to make a lasting impact on the biosimilars market.
- Biocon Biologics acquires Viatris’ biosimilars for nearly $3 billion.
- The deal includes a $2.3 billion payment and $1 billion in preference shares.
- Biocon aims to strengthen its global presence in developed markets.
- The transition will be supported by Viatris for two years.
- Both companies share commercialization rights for key biosimilars, enhancing patient access.
Read more → www.ajmc.com